Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the ...

Diagnostics company Guardant Health (NASDAQ:GH) in Q2 CY2025, with sales up 30.9% year on year to $232.1 million. The company ...

Q2 2025 Management View Helmy Eltoukhy, Co-CEO, stated that "Q2 marked another exceptional quarter for Guardant. We continue to build momentum across oncology, biopharma and screening business lines, ...

Second Quarter 2025 Results Key Financial Results Revenue: US$232.1m (up 31% from ...

James Van Der Beek and Guardant are partnering for a campaign focused on colorectal cancer. Guardant Health announced a ...

Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.

Discover Guardant Health's FDA breakthroughs & revenue growth! Learn why profitability-focused investors might hold back ...

With rates of colorectal cancer (CRC) surging among younger populations, Guardant Health is turning to a famous face beloved ...

Van Der Beek is opening up about his colon cancer to increase awareness of the importance of early detection, especially as ...

Guardant Health, Inc. ( NASDAQ: GH) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET AmirAli Talasaz - Co-CEO & Director Helmy Eltoukhy - Co-Founder, Co-CEO & Chairman Michael Bell - Chief ...

James Van Der Beek, whose net worth is $6 million, as per Celebrity Net Worth, has partnered with Guardant Health to raise ...

Guardant Health thinks around 700,000 patients in the U.S. could eventually benefit from advanced-stage cancer screening, which would drive up sales to around $6 billion annually.